Kindeva, a global CDMO and drug delivery expert, and Rocket Science Health (RSH), a Canadian technology healthcare company, have joined forces to find partners to develop a new intranasal delivery platform. RSH’s cutting-edge technology, combined with Kindeva’s CDMO capabilities, will supercharge the product journey as RSH prepares for commercial readiness.

The non-exclusive agreement will see Kindeva and RSH identify partners for the development of the ‘RSH Olfactory Delivery Device,’ a dual nostril intranasal platform used for precisely targeting specific regions of the nasal cavity. The device has the ability to deposit the majority of a drug dose into the Olfactory Clefts. The Olfactory Clefts are both a desirable target for drug deposition, and yet, historically a difficult location to reach due to the complex human nasal anatomy. Early research suggests the device has the potential to achieve high deposition by ejecting a laminar stream, as compared to conventional intranasal treatments which eject a plume spray or mist. Further, the RSH technology overcomes complex nasal anatomy through the device’s proprietary dispensing tips that extend past the nasal valve to an optimal vantage point. Another feature of the RSH technology that sets it apart is attention to human factors to ensure the device is accessible, comfortable, and easy to use correctly for accurate dosing, especially among cognitively and or physically impaired patients, and for self-administration.

Kenneth Irving, Founder of Rocket Science Health said: “A personal experience with an unreliable delivery method opened my eyes to the influence of drug devices on health outcomes. That realisation led to the founding of Rocket Science Health and nearly a decade of rethinking intranasal delivery. Knowing subregions of the nasal cavity provide access to different organ systems, most notably the CNS via the Olfactory Clefts, we redesigned the fluidics and user experience to enable precise, targeted delivery. Now, we are ready to bring this technology into clinical trials for advancing dose dependent medicine. Kindeva stood out not only for their track record of supporting drug developers through the trial process, but for their history and shared commitment to making meaningful innovations widely accessible.”